Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features

Area of Science:

• Oncology
• Cancer Biology
• Molecular Therapy

Background:

• Targeted cancer therapies face challenges from treatment resistance, particularly in drug-sensitive genotypes.
• Adaptive resistance mechanisms can rapidly emerge, limiting therapeutic efficacy.
• Cancer stem-like cells are implicated in treatment resistance across various cancers.

Purpose of the Study:

• To investigate the role of cancer stem-like cells in mediating adaptive resistance to targeted therapies.
• To explore combination strategies involving oncogene ablation and stem-targeting agents.

Main Methods:

• Utilized ALK-translocated lung cancer cell lines (H3122, H2228) with cancer stem-like cell features.
• Administered oncogene ablative therapy (ALK inhibitor) combined with PI3K inhibitor or salinomycin.
• Assessed reversal of cancer stem-like cell features, colony formation, and acquired resistance.

Main Results:

• Cancer stem-like cells with high stem cell marker expression and in vivo tumorigenesis mediated adaptive resistance to ALK inhibition.
• Combined therapy reversed cancer stem-like cell features and reduced colony formation.
• Co-targeting blocked the development of acquired resistance in H3122 cells.

Conclusions:

• Cells with cancer stem-like features can mediate adaptive resistance to targeted therapies.
• A stochastic model governs the emergence of resistance in these cells.
• Concurrent therapy with oncogene ablating agents and stem-like cell-targeting drugs is crucial for maximizing therapeutic efficiency.